Streetbeat News

ICCM

IceCure Medical Ltd

https://www.icecure-medical.com

Industry

Medical - Devices

IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

Open

0.72

Mkt cap

32M

Volume

3.3M

High

0.75

P/E Ratio

-2.25

52-wk high

1.57

Low

0.65

Div yield

N/A

52-wk low

0.48

The FDA Advisory Panel has voted in favor of IceCure Medical's ProSense® cryoablation technology for early-stage low-risk breast cancer, with a decision on marketing authorization expected in Q1 2025.

Portfolio Pulse from

November 08, 2024 | 12:15 pm

IceCure Medical shares rose following the announcement of significant public comments from key stakeholders before the FDA panel review for ProSens® cryoablation in early-stage low-risk breast cancer.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 2:36 pm

IceCure Medical announced that numerous public comments from key stakeholders have been posted ahead of the FDA Advisory Panel meeting on November 7, 2024, for the marketing authorization of its ProSense Cryoablation System for early-stage low-risk breast cancer.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 12:39 pm

IceCure Medical has received a Notice of Allowance from the U.S. Patent Office for its next-generation cryoablation system, which includes innovative technology for enhanced usability and cryogen integrity. The XSense system, already FDA-cleared, is set to address needs in the $1.67 billion global tumor ablation market.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 12:34 pm

IceCure's ProSense Cryoablation technology was highlighted in six global studies at the 2024 EUSOBI Conference. The ICE3 trial results, presented by Dr. Kenneth Tomkovich, won the EUSOBI Abstract Award. The THERMAC trial showed a 94% complete ablation rate for breast cancer using cryoablation. IceCure also conducted hands-on demonstrations at the event.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 12:18 pm

IceCure Medical Ltd. (NASDAQ: ICCM) announced the publication of its ICE3 trial results in the Annals of Surgical Oncology, showing a 96.3% recurrence-free rate for early-stage, low-risk breast cancer treated with ProSense cryoablation. The publication precedes an FDA Advisory Panel Meeting for marketing authorization of ProSense, scheduled for November 7, 2024.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 12:17 pm

IceCure Medical's ProSense cryoablation technology has been highlighted in a study published in The British Journal of Radiology, demonstrating a 97.7% technical success rate in treating tumors of the lung, bone, and soft tissues. The study, conducted at the European Institute of Oncology, found ProSense to be safer, more cost-effective, and easier to manage compared to argon-based systems.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:03 pm

HC Wainwright & Co. has reiterated its Buy rating on Icecure Medical (NASDAQ:ICCM) and maintained a price target of $2.5.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 6:00 pm

IceCure Medical Ltd. (NASDAQ:ICCM) announced that the FDA Advisory Panel will meet on November 7, 2024, to discuss the marketing authorization of ProSense, a cryoablation technology for early-stage low-risk breast cancer. A decision is expected by early 2025.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 12:09 pm

IceCure Medical Ltd. (NASDAQ:ICCM) has received a Notice of Allowance from the USPTO for a continuation patent on its 'Cryogenic Pump' technology, enhancing its global IP leadership in cryoablation technologies. This patent broadens the applications of IceCure's platform, with over 50 patents issued worldwide.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 12:32 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.